Ovid Therapeutics
OVID
91 hedge funds and large institutions have $144M invested in Ovid Therapeutics in 2020 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 22 increasing their positions, 29 reducing their positions, and 12 closing their positions.
100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 12
63% more call options, than puts
Call options by funds: $760K | Put options by funds: $465K
15% more funds holding
Funds holding: 79 → 91 (+12)
0.25% less ownership
Funds ownership: 39.91% → 39.66% (-0.25%)
11% less capital invested
Capital invested by funds: $161M → $144M (-$17.1M)
24% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 29
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$16.7M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$8.36M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$8.23M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$7.34M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$18.9M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$4.98M |
| 3 |
Renaissance Technologies
New York
|
-$4.6M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$3.76M |
| 5 |
Millennium Management
New York
|
-$3.25M |
OVID Hedge Fund Activity: Q3 2020 in Review
91 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q3 2020, worth a combined $144M — down 11% from $161M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new OVID positions and 12 closed out — a net gain of 12 holders — while 22 added to existing stakes and 29 trimmed.
The largest buyer was Artal Group, opening a new position worth an estimated $16.7M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $18.9M sold.
- 91 institutional investors held Ovid Therapeutics (OVID) as of Q3 2020, up from 79 in Q2 2020.
- Funds reported $144M of Ovid Therapeutics stock for Q3 2020, down 11% quarter-over-quarter.
- 24 funds opened new Ovid Therapeutics positions in Q3 2020 and 12 closed out, a net change of +12 holders.
- The largest Ovid Therapeutics buyer in Q3 2020 was Artal Group, an estimated $16.7M added.
- The largest Ovid Therapeutics seller in Q3 2020 was Consonance Capital Management, an estimated $18.9M sold.
Based on aggregated 13F filings for Q3 2020.